As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...

Senseonics earns a buy with Eversense 365 driving growth, Q3 revenue up 90% YoY, gross margin expansion, and Ascensia ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...

A method using light to measure blood glucose levels could save diabetes patients from frequent finger pricks every day.

Optical sensors are a broad class of device for detecting light intensity. This can be just a simple component for notifying when ambient light levels rise above or fall below a prescribed level, or a ...

While fluorophore-biomacromolecule systems are relatively well known, afterglow luminophore-biomacromolecule conjugates/complexes are rarely studied. Here, the authors report the development of a ...